Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3927]

PARP inhibitors in prostate cancer: Guidelines, who to test and the patient...

Dr Neal Shore and Dr Elena Castro

PARP inhibitors in prostate cancer: Guidelines, who to test and the patient pathway ( Dr Neal Shore and Dr Elena Castro )

New emerging treatment options and targeted therapies for bladder cancer

Dr Arlene Siefker-Radtke and Dr Yohann Loriot

New emerging treatment options and targeted therapies for bladder cancer ( Dr Arlene Siefker-Radtke and Dr Yohann Loriot )

Conducting Oncology Clinical Trials in Africa II: ACTC Informational Session

Prof Folakemi Odedina, Prof Ifeoma Okoye and Prof Delva Shamley

Conducting Oncology Clinical Trials in Africa II: ACTC Informational Session ( Prof Folakemi Odedina, Prof Ifeoma Okoye and Prof Delva Shamley )

Timing of response to venetoclax combination treatment in older patients with...

Dr Brian Jonas - University of California Davis Comprehensive Cancer Center...

Timing of response to venetoclax combination treatment in older patients with acute myeloid leukaemia ( Dr Brian Jonas - University of California Davis Comprehensive Cancer Center, Sacramento, USA )

CheckMate 227 three-year update: Nivolumab plus ipilimumab versus chemo as...

Prof Suresh Ramalingam - Winship Cancer Institute of Emory University, Atlanta...

CheckMate 227 three-year update: Nivolumab plus ipilimumab versus chemo as first-line treatment for advanced NSCLC ( Prof Suresh Ramalingam - Winship Cancer Institute of Emory University, Atlanta, USA )

ASCO 2020: Latest developments in EGFR-mutated non-small cell lung cancer

Prof Benjamin Besse and Dr Alex Spira

ASCO 2020: Latest developments in EGFR-mutated non-small cell lung cancer ( Prof Benjamin Besse and Dr Alex Spira )

Ensuring quality care for breast cancer patients globally

Dr Didier Verhoeven - University of Antwerp, Antwerp, Belgium

Ensuring quality care for breast cancer patients globally ( Dr Didier Verhoeven - University of Antwerp, Antwerp, Belgium )

Venetoclax with bortezomib and dexamethasone in relapsed/refractory multiple...

Dr Shaji Kumar - Mayo Clinic, Rochester, USA

$Venetoclax with bortezomib and dexamethasone in relapsed/refractory multiple myeloma ( Dr Shaji Kumar - Mayo Clinic, Rochester, USA )$

KRd vs VRd for initial therapy of newly diagnosed multiple myeloma

Dr Shaji Kumar - Mayo Clinic, Rochester, USA

KRd vs VRd for initial therapy of newly diagnosed multiple myeloma ( Dr Shaji Kumar - Mayo Clinic, Rochester, USA )

Teclistamab for patients with heavily pretreated relapsed or refractory...

Dr Saad Usmani - Levine Cancer Institute, Charlotte, USA

$Teclistamab for patients with heavily pretreated relapsed or refractory multiple myeloma ( Dr Saad Usmani - Levine Cancer Institute, Charlotte, USA )$

E2108: Systemic therapy plus early local therapy versus systemic therapy alone...

Dr Seema Ahsan Khan - Northwestern Memorial Hospital, Chicago, USA

E2108: Systemic therapy plus early local therapy versus systemic therapy alone in women with de novo stage IV breast cancer ( Dr Seema Ahsan Khan - Northwestern Memorial Hospital, Chicago, USA )

KEYNOTE-604: Pembrolizumab plus etoposide and platinum as a first-line therapy...

Dr Charles Rudin - Memorial Sloan Kettering Cancer Center, New York City, USA

KEYNOTE-604: Pembrolizumab plus etoposide and platinum as a first-line therapy for extensive-stage small-cell lung cancer ( Dr Charles Rudin - Memorial Sloan Kettering Cancer Center, New York City, USA )

More from ecancer